Clinical aspects of very-low-birthweight infants showing reopening of ductus arteriosus

Pediatrics International

Volumn 53, Issue 3, 2011, Pages 322-327

  Uchiyama, Atsushi ^a,b   Nagasawa, Hiroyuki ^a   Yamamoto, Yutaka ^a   Tatebayashi, Koji ^a   Suzuki, Hiroko ^a   Yamada, Keitaro ^a   Arai, Mayuki ^a   Kohno, Yoshinori ^a  

^a GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

chronic lung disease; ductus arteriosus reopening; indomethacin; patent ductus arteriosus; very low birthweight infants

Indexed keywords

INDOMETACIN; MEFENAMIC ACID;

ARTICLE; CHRONIC LUNG DISEASE; CLINICAL FEATURE; DUCTUS ARTERIOSUS REOPENING; FEMALE; HEART DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; VERY LOW BIRTH WEIGHT;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS, PATENT; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79959744362     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2010.03251.x     Document Type: Article

References (16)

1. Knight DB,. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin. Neonatol. 2001; 6: 63-73. (Pubitemid 32127004)
2. Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M,. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: A pilot study. Pediatrics 2003; 112: e354.
3. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS,. Effects of indomethacin in premature infants with patent ductus arteriosus: Results of a national collaborative study. J. Pediatr. 1983; 102: 895-906. (Pubitemid 13058794)
4. Rennie JM, Cooke RW,. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch. Dis. Child. 1991; 66: 55-8.
5. Weiss H, Cooper B, Brook M, Schlueter M, Clyman R,. Factor determining reopening of the ductus arteriosus after successful complete closure with indomethacin. J. Pediatr. 1995; 127: 466-71.
6. Keller RL, Clyman RI,. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics 2003; 112: 583-7. (Pubitemid 37082111)
7. Skinner J,. Diagnosis of patent ductus arteriosus. Semin. Neonatol. 2001; 6: 49-61. (Pubitemid 32127003)
8. Papile LA, Burstein J, Burstein R, Koffler H,. Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gm. J. Pediatr. 1978; 92: 529-34. (Pubitemid 8293290)
9. Volpe JJ,. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr. Res. 2001; 50: 553-62. (Pubitemid 33009976)
10. Committee for the classification of prematurity: An international classification of retinopathy of prematurity. Arch. Opthamol. 1984; 102: 1130.
11. Shennan AT, Dunn MS, Ohalsson A, Lenox K, Hoskins EM,. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82: 527-32.
12. Yanai H,. Stacel 2-The Useful Add-In Software Forms on Excel, 2nd edn. OMS, Tokyo, Japan, 2004.
13. Miller SP, Mayer EE, Clyman RI, Glidden DV, Hamrick EG,. Prolonged indomethacin exposure is associated with decreased white matter injury detected with magnetic resonance imaging in premature newborns at 24 to 28 weeks' gestation at birth. Pediatrics 2006; 117: 1627-31.
14. Quinn D, Cooper B, Clyman RI,. Factor associated with complete closure of the ductus arteriosus: A role for prolonged indomethacin therapy. Pediatrics 2002; 110 (1 Pt 1): e10.
15. Brown E,. Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. J. Pediatr. 1979; 95: 865-6. (Pubitemid 10209777)
16. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM,. Risk factors for chronic lung disease in the surfactant era: A North Carolina population-based study of very low birth weight infants. Pediatrics 1999; 104: 1345-50.